Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSRD-100 (desoximetasone) in atopic dermatitis
NCT02677610Phase 3Withdrawn
- Sponsor
- Merz
- Primary completion
- Jul 2016
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing MSRD-100 Gel with Vehicle Gel (2 arms). Primary endpoint: Proportion of subjects with treatment success at 28 days. Status: withdrawn.
02
Drugs
desoximetasone
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02677610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677610.